Tissue Engineering in Dentistry. by Neel, EA et al.
Review
Tissue engineering in dentistry
Ensanya Ali Abou Neel a,b,c,*, Wojciech Chrzanowski d,e, Vehid M. Salih c,h,
Hae-Won Kim e,f,g, Jonathan C. Knowles c,e
aDivision of Biomaterials, Operative and Aesthetic Department Biomaterials Division, King Abdulaziz University,
Jeddah, Saudi Arabia
bBiomaterials Department, Faculty of Dentistry, Tanta University, Tanta, Egypt
cUCL Eastman Dental Institute, Biomaterials & Tissue Engineering, 256 Gray’s Inn Road, London WC1X 8LD, UK
dThe University of Sydney, The Faculty of Pharmacy, NSW 2006 Sydney, Australia
eDepartment of Nanobiomedical Science & BK21 Plus NBM Global Research Center for Regenerative Medicine,
Dankook University, Cheonan 330-714, Republic of Korea
f Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan 330-714, Republic of Korea
gDepartment of Biomaterials Science, College of Dentistry, Dankook, University, Cheonan 330-714, Republic of Korea
h Plymouth University Peninsula School of Medicine & Dentistry, Drake’s Circus, Plymouth PL4 8AA, Devon, UK
j o u r n a l o f d e n t i s t r y 4 2 ( 2 0 1 4 ) 9 1 5 – 9 2 8
a r t i c l e i n f o
Article history:
Received 3 May 2014
Received in revised form
15 May 2014
Accepted 17 May 2014
Keywords:
Tissue engineering strategies
Biomimetic scaffolds
Dentine-pulp complex
Bioengineered teeth
a b s t r a c t
Objectives: of this review is to inform practitioners with the most updated information on
tissue engineering and its potential applications in dentistry.
Data: The authors used ‘‘PUBMED’’ to find relevant literature written in English and
published from the beginning of tissue engineering until today. A combination of keywords
was used as the search terms e.g., ‘‘tissue engineering’’, ‘‘approaches’’, ‘‘strategies’’ ‘‘den-
tistry’’, ‘‘dental stem cells’’, ‘‘dentino-pulp complex’’, ‘‘guided tissue regeneration’’, ‘‘whole
tooth’’, ‘‘TMJ’’, ‘‘condyle’’, ‘‘salivary glands’’, and ‘‘oral mucosa’’.
Sources: Abstracts and full text articles were used to identify causes of craniofacial tissue
loss, different approaches for craniofacial reconstructions, how the tissue engineering
emerges, different strategies of tissue engineering, biomaterials employed for this purpose,
the major attempts to engineer different dental structures, finally challenges and future of
tissue engineering in dentistry.
Study selection: Only those articles that dealt with the tissue engineering in dentistry were
selected.
Conclusions: There have been a recent surge in guided tissue engineering methods to
manage periodontal diseases beyond the traditional approaches. However, the predictable
reconstruction of the innate organisation and function of whole teeth as well as their
periodontal structures remains challenging. Despite some limited progress and minor
successes, there remain distinct and important challenges in the development of reproduc-
ible and clinically safe approaches for oral tissue repair and regeneration. Clearly, there is a
convincing body of evidence which confirms the need for this type of treatment, and public
health data worldwide indicates a more than adequate patient resource. The future of these
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therapies involving more biological approaches and the use of dental tissue stem cells is
promising and advancing. Also there may be a significant interest of their application and
wider potential to treat disorders beyond the craniofacial region.
Clinical Significance: Considering the interests of the patients who could possibly be helped
by applying stem cell-based therapies should be carefully assessed against current ethical
concerns regarding the moral status of the early embryo.
# 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Tissue loss due to trauma, disease or congenital abnormalities
is a major health care problem worldwide. When this occurs in
the craniofacial region, it induces serious physiological and
psychological consequences on patients. Reconstruction of
the craniofacial area to its aesthetic and functional level is
therefore a desire of affected patients.1 This review addresses
the concentrated research effort in methods for oro-facial
reconstruction from using medical devices and tissue grafts to
a more explicit tissue engineering approach. It is an approach
that utilises specific biodegradable synthetic or natural
scaffolds as well as advanced molecular techniques in order
to replace tissue function. The types of scaffold and
methodologies used to enable cells to function in an
appropriate manner to produce the required extracellular
matrix and ultimately a tissue of a desired geometry, size and
composition are briefly considered here.
There has been a clear and distinct hypothetical shift in
regenerative medicine from using medical devices and whole
tissue grafts, to a more explicit approach that utilises specific
bioactive, biodegradable synthetic or natural scaffolds com-
bined with cells and/or biological molecules, to create a
functional replacement tissue in a diseased or damaged site.
Every era in medical research over the past 50 years, involving
the use of biomaterials in order to replace tissue function, has
been distinct and identified by particular developmental
successes and materials. For example, in the 1950s, there
was a predominant use of metal implants and associated
devices with little thought offered to the effects on local
tissues, let alone the cells. Throughout the ‘70s and ‘80s, there
was a significant increase in the use of polymers and synthetic
materials where researchers considered both biological and
material properties. More recently, there has been a distinct
and concentrated effort in the design and use of both natural
and degradable scaffolds and advanced biological consider-
ation of the materials.
There has been an evolution from the use of biomaterials to
simply replace non-functioning tissue to that of utilising
specific materials, which will nurture, in three dimensions, a
fully functioning and structurally acceptable regenerated
tissue. Thus, the simple needs to accomplish the replacement
of a functioning joint using wholly metal prostheses in the ‘60s
has been markedly enhanced to concentrate on biological
aspects of the damaged or diseased tissue to be replaced by
repaired, or better still, totally regenerated tissue. There was a
very naı¨ve belief that materials were typically ‘inert’ and it has
been rightly suggested that this is a misleading interpretation,as it became clear that materials could indeed change
physically and chemically following implantation. Certainly
from a biological perspective, no material should be consid-
ered (or indeed is) inert.
This review will therefore deal with the significant
advancements that have been made in the tissue engineering
field as well as its future potential.
2. Strategies of tissue engineering
In this section, cell injection, cell induction and cell seeded
scaffold will be briefly described as different but inter-related
approaches of tissue engineering. These approaches depend
on the use of one or more key elements e.g., cells, growth
factors and matrix2 to guide tissue regeneration.
2.1. Cell injection therapy
Since the tissue formation resulted from cellular action,
injection of inherently intelligent cells, stem cells in particular,
into the defect have been suggested to regenerate tissues. The
effectiveness of this therapy however is limited by low
engraftment and inadequate localisation of injected cells
particularly in areas showing continuous movement e.g.,
beating heart.4 Immunological rejection and the ability of the
injected cells to maintain their phenotype are other chal-
lenges.3 For adequate localisation and prevention of direct
contact with the immune system, using a delivery vehicle to
carry and deliver the material has been attempted.4 It has been
observed that cells encapsulated into a delivery vehicle were
able to proliferate and differentiate.5 Thanks to these
advantages, this strategy seems to be promising in bone
and cartilage repair.6 It also opened new opportunities to
reduce the morbidity and mortality rate caused by heart
failure in ischaemic heart patients.7 But again, the delivery
vehicle has to be made from a smart material that can be easily
injected but finally solidified at body temperature. Further-
more, the release of cells has to be controlled by the need of the
body.
For this strategy, stem cells are the most successful
candidate. According to their potency, stem cells are classified
into totipotent (generate all differentiated cells in an organism
e.g., fertilised egg), pluripotent (form the three germ layers;
ectoderm, endoderm and mesoderm e.g., embryonic stem
cells), multipotent (differentiate into several cell lines but with
more restricted number of phenotypes e.g., mesenchymal
stem cells), oligopotent (differentiate into a few cell types e.g.,
myeloid stem cells) and unipotent cells (i.e., differentiate into
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stem cells are classified into embryonic and adult (somatic).
Embryonic stem cells have a great potential use in regenera-
tive medicine as they can be maintained indefinitely in an
undifferentiated state in culture. Embryonic stem cells
showed a major advantage in medical research, understand-
ing the range of transformation of such cells can help in the
correction of many mutational errors. While the necessity of
using and manipulating embryonic stem cells to produce fully
differentiated cells for tissue regeneration is inexpressible, the
ethical and legal view points of using the embryo or foetal
tissues as a source of these cells must be weighed.
2.2. Cell induction therapy
Due to the limitations with cell injection therapy, there has been
a clear and distinct shift to recruiting the circulating body cells
to regenerate the tissues. With respect to osteoinduction, an
important consideration when dealing with craniofacial bone
regeneration, it is very important to understand the underlying
biological mechanisms that facilitate osteinduction. This is
highlighted very elegantly in the review of Miron and Zhang.9
Furthermore, the ideal design of any osteoconductive material
would mean that no exogenous biological components would
be needed in order to induce osteogenesis. However, exogenous
factors are still utilised in the form of injecting the signalling
molecules e.g., growth/differentiation factors, to modulate the
cell behaviour. Example of these factors include; fibroblasts
growth factors-2 and 9 (FGFs-2 and -9),10 transforming growth
factors b1 (TGF-b1),11 vascular endothelial growth factors
(VEGFs),12 recombinant human growth/differentiation factor-
5 (rhGDF-5)13 and bone morphogenetic protein.14 Although, this
therapy was effective in regenerating some tissues,15 the
expense of purification and the development of an appropriate
carrier to deliver these factors to their target sites limit itsPatient
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suspensions from a tissue biopsy are described in details by Toscope.16 Taking a step back, injection of the genetic information
instead has been thought to produce a population of progenitor
cells to over-express the growth/differentiation factors neces-
sary for modulating cell behaviour.17 Choosing gene(s) for the
required protein(s), timing of gene expression, type of gene
vector (viral or non-viral), and method of gene delivery
(systematic or local) have to be considered when employing
gene therapy.18
2.3. Cells seeded scaffolds
Combining all the previous attempts together led to the
emergence of another strategy to engineer tissues. This strategy
depends on the isolation of appropriate cell population from a
biopsy taken from the patient or a donor. And the most likely
candidate for such therapies remains the Mesenchymal Stem
Cell (MSC). The potent immunomodulatory and anti-inflam-
matory properties of human oral mucosa-/gingiva-derived
MSCs places them as a very strong potential cell source for
MSC-based therapies for wound repair and a wide range of
inflammation-related diseases. Zhang et al.19 quite correctly
asked, whether these MSCs differ from bone marrow stem cells
in terms of host defence immune response, because of their
specific anatomic location in the oral cavity? Answering such
queries will substantially enhance our understanding of the
biological properties of oral mucosa-/gingiva-derived MSCs and
their important roles in tissue regeneration and cell-based
therapy of immune- and/or inflammation-related diseases. In
addition, MSCs although initially considered as having the
potential to differentiate into only tissue-specific cells for
regenerative medicine, are now being recognised as an essential
cell type that possesses important immunomodulatory prop-
erties capable of treating a variety of immune-related diseases.
MSCs can thus regulate the intensity of immune response by
inducing T-cell apoptosis, which could have great therapeuticxpansion of  ce lls
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applications.20 The isolated cells will then be expanded in
culture and finally seeded within or onto a natural or synthetic
scaffold that define the shape of the tissue and supports cells
during their growth21 (Fig. 1). Ideally, cells adhere to the scaffold,
proliferate, differentiate and form the required tissue. Then the
newly formed ‘‘organoid’’ can be then transplanted into the
patient. Another option for this strategy relies on implantation
of acellular scaffolds into the defect while the body cells can
populate the scaffold to form the new tissue in situ. Gupte and
Ma22 clearly recognised that three-dimensional scaffolds
artificially create a multi-scale environment capable of direct-
ing cell adhesion, proliferation, and importantly, differentia-
tion. These authors also clearly recognised significant technical
challenges which need to consider the synergistic integration of
key structural cues with relevant biological molecules for cell-
based therapies in order to achieve properly functioning dental
and craniofacial tissue regeneration.
3. Engineered orofacial tissues
Orofacial structures are very unique in their development and
function. Orofacial bones, for example, are derived from both
neural crest and paraxial mesoderm; the skeletal bones
however derived from mesoderm. Furthermore, orofacial
bones undergo significant stress and strain produced from
different muscles of mastication and respond differently to
growth factors and mechanical stimuli.24 Furthermore, oro-
facial tissues have limited and variable capacity for regenera-
tion. Unlike alveolar bones, cementum has a very slow
regenerative capacity.25 Unlike enamel, dentine can regener-
ate. As it is encased in dentine and has limited apical blood
supply, the pulp has a limited capacity for regeneration.26
Statistics on tooth loss indicated that in US >20 million
people are missing all of their teeth, and >100 million have lost
11–15 teeth.27 Dental implants have been advocated as tooth
replacement; lack of adequate bone support and the proximity
to anatomic structures e.g., maxillary sinus and inferior alveolar
canal are the most frequently encountered problems. Using
bone grafts to provide bone support has been attempted; the
success however was limited.28 Tissue engineering, therefore,
found an interest as the clinically relevant approach to
regenerate dental tissues as well as the whole tooth. The first
attempt involved the application of calcium hydroxide for
regeneration of dentine and pulp in traumatically exposed
teeth.29 The field of tissue engineering has then grown
tremendously to the development of fully functional bioengi-
neered tooth.30 This section covers the progress made to reach a
destiny where a fully functional bioengineered tooth becomes a
reality. It also covers the tissue engineering attempt to replace
soft tissues (skin, mucosa, muscles and salivary glands), bone
and temporomandibular joints (TMJ). Each section was ended
by the authors’ opinion as discussed later.
3.1. Dentine-pulp complex
The regeneration of the dentine-pulp complex, obtained with
pulp capping materials (e.g., calcium hydroxide, mineral
trioxide aggregates, Biodentine1), has been correlated withthe stimulation of differentiation of the pulp progenitor cells
into odontoblast-like cells29 or secretion of TGF-b131 which
plays a key role in angiogenesis, recruitment of progenitor
cells, cell differentiation and finally mineralisation of the
injured area. Stem cell therapy has been attempted for
regeneration of the dentine-pulp complex. Dental tissues
are a very rich source of stem cells. Examples of these tissues
include e.g., pulp,32 apical papilla,33 human retained34 or
exofoliated deciduous teeth,35 oral mucosa and gingiva.19
Subcutaneous injection of stem cell-sheet derived pellet at the
back of a mice induced the formation of the dentine-pulp
complex.33 Encapsulated stem cells were also used for
dentine-pulp regeneration; examples of materials employed
for cell encapsulation include enzyme-cleavable, customised
self-assembled peptide hydrogels,36 PEGylated fibrin hydro-
gels37 or biodegradable lactide and glycolide.11 The encapsu-
lated cells were also effective in dentine-pulp regeneration.
For example, Gelfoam-encapsulated dental stem cells stimu-
lated the formation of the dentine-pulp complex in pulpless
root canals in young permanent incisors in beagles.38 Cell-free
scaffolds e.g., Emdogain gel39 or combination of Emdogain and
platelet rich plasma40 stimulated the regeneration of the
dentine-pulp complex. Growth factors [e.g., fibroblast growth
factor basic (FGF), transforming growth factor b1 (TGF-b1) and
endothelial growth factor (EGF)] have been also included
within the scaffolds to modulate the function of stem cells.11
Due to the size and confinement of the pulp within the root
canal(s), cell therapy and/or injectable hydrogels represented
the common strategic approach for engineering the dentine-
pulp complex. With this approach, however, the highly
organised and specialised nature of such complex e.g.,
presence of different cell layers in a specific order and dentine
on the periphery of pulp, has not been considered. Thorough
investigations are required to develop a technology that allows
designing such hierarchical structure while injecting the
hydrogels scaffolds to shape the dentine-pulp complex and
to allow preferential arrangement of different type of cells and
hence the tissues in the innate order.
3.2. Periodontium
Periodontitis is a widespread condition of inflammation that
causes destruction of tooth supporting connective tissues
(gingiva, alveolar bone, periodontal ligament and root cemen-
tum) and eventually teeth loss (Fig. 2a). Regeneration of tooth
supporting structures i.e., cementum-periodontal ligament-
bone interfaces and structures are very challenging and
require the synergy of all cellular and molecular events
involved in regeneration of these complex tissues. This
section covers the progress from guided bone/tissue regener-
ation to the most recent advances in tissue engineering
employed to replace the lost tooth supporting structures in an
attempt to maintain natural dentition.
Guided tissue/bone regeneration membrane (GTR/GBR)
utilises occlusive membranes to maintain the defective space,
selectively encourage the appropriate cells to regenerate the
lost tissues and support the newly formed tissues.41 GTR/GBR
was employed to treat periodontal42 and alveolar43 defects as
well as to maintain integrity of alveolar bone following
teeth extraction.44 Several synthetic polymers were used as
Fig. 2 – A schematic representation of (a) the endogenous approach used for regeneration of periodontal tissues adopted
from.61 E: enamel, D: dentine, P: pulp, G: gingival, PL: periodontal ligament and AB: alveolar bone NPL: new periodontal
ligament, NB: new bone, NC: new cementum and (b) a strategy to engineer a whole tooth.
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(PTFE, Gore- Tex1),45 polylactide (e.g., Vivosorb1& Epi-Gide1),
glycolide (Gore Resolut Adapt1) and polylactide/glycolide.46
Biomimetic materials, collagen in particular, has been
advocated as alternative to synthetic polymers; examples of
collagen membranes include; OssixtTM, Bio-Gide1, Neomem1,
BiomendTM, Biomend ExtendtTM.47 To enhance tissue regen-
eration, negatively charged collagen membranes were devel-
oped.48 To control the degradability and hence enhance the
osteogenic potential of collagen membranes, immobilisation
of hydroxyapatite nanoparticles,49 alkaline phosphatase42 or
bioactive glass50 on collagen membranes has been also
attempted. The recent advances in the field of tissue
engineering utilises growth factors and cytokines for peri-
odontal regeneration.51 Examples of growth factors used
include transforming growth factor b1 (TGFb1), fibroblast
growth factor-2 (FGF-2), bone morphogenic protein-2 (BMP-2),
recombinant human bone morphogenic protein-2 (rhBMP-2).
Soaking collagen membranes in BMP-2 or TGFb1 enhanced the
cellular activity of human osteoblasts in vitro.52 Incorporation
of FGF-2 enhanced the bone regeneration capacity of collagen
membranes in a rat calvarial defect.53 Contradicting results,
however, were obtained clinically. For example, no complete
periodontal regeneration was attained with combined therapy
of collagen membrane and BMP.54 On the other hand, the five-
year survival rate was 100% with excellent clinical and
radiographic outcomes was seen for rhBMP-2 combined withcollagen membranes.55 Although there is some degree of
success in treating craniofacial, cleft palate, bone and cartilage
defects56 bacterial infection is a common problem with GTR/
GBR membranes. Incorporation of tetracycline,57 chlorhexi-
dine58 and zinc59 could overcome this problem. The antibac-
terial agent could be very effective provided that its release is
well controlled. More recently, developments in bone repair/
regeneration using carbon nanotubes or carbon nanotube-
based composites (i.e. CNT associated with different biological
molecules or polymers) have been identified as a innovative
biomaterial for oral tissue regeneration. Indeed, Martins-
Junior et al.60 provided an excellent overview of bone tissue
engineering focusing on the potential actions of CNT in bone
formation and repair/regeneration.
Regardless of the clinical effectiveness of collagen mem-
branes in combination with bone graft or substitutes or growth
factors, the in vivo degradation of collagen could be too fast to
enable tissue regeneration in large defects in particular. Space
maintenance and tissue occlusion properties could be also
challenging in this situation; therefore the utilisation of a
membrane with ideal mechanical, degradation properties but
still maintaining excellent biocompatibility is still required. For
such a case, the application of multilayered membranes
combining a layer of flexible synthetic polymer (e.g., polylac-
tide-co-glycolide dimethacrylate) encased between two layers
of natural polymers (e.g., collagen) could be an option. The
flexibility of the synthetic polymer provides better handling,
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degradation can be controlled by adjusting the molecular
weights and the ratio of polylactide to polyglycolide segments.
Collagen however provides an excellent biocompatibility and
enhanced cellular response. Another direction would be the use
of biologically active nanofibrous scaffolds. The resemblance to
ECM and the presence of large pores could be an attractive for
cells invasion and proliferation. To fabricate nanofibrous
scaffolds with a wide range of properties, a combination of
both synthetic and natural polymers can be employed.
Endogenous regenerative technology ‘‘ERT’’ depends on
key endogenous resources (e.g., cells or growth factors and
proteins) for regeneration of functional tissues (Fig. 2b). Cell
homing or cell transplantation are meritorious promising
approaches, that rely on cells, to completely and reliably
restore the periodontium.62 For cell homing, a material niche
(e.g., autogenic growth factors in combination with fibrin and
Emdogain and Bio-Oss) is required to recruit the host stem
cells to regenerate the periodontium. The choice and deign of
each niche component as well as the invasiveness of the
clinical procedures would affect the clinical outcome.61 Cell
transplantation could be another option for periodontium
regeneration. For example, injection of autogenic gingival
stem cells encapsulated within collagen or deproteinized
bovine cancellous bone scaffold showed a significant im-
provement in periodontal tissue regeneration of miniature
pigs.63 Injection of autogenic fibroblasts was found to be safe
and effective in restoring the interdental papillae in a
randomised controlled study carried out on 20 patients.64
The use of platelet rich plasma (PRP) as a source of key
endogenous growth factors and proteins involved in tissue
regeneration has been also employed to reliably regenerate
periodontium. PRP increased the proliferation, differentiation
and hence odontogenic and osteogenic gene expression of
human periodontal ligament and dental pulp stem cells.
Combination of PRP with either human cultured periosteum/
hydroxyapatite65 or with patient’s own mesenchymal stem
cells66 was effective in periodontal regeneration. A specific
concentration of PRP however is required for periodontal
regeneration around implant67 or replanted teeth.68 Beyond
this concentration, an inhibition of cellular activities were
recognised.69 Furthermore, the relative proportion of PRP
components, duration and timing of exposure should also be
optimised.69
The third generation of periodontal regeneration strate-
gies, following GBR/GTR and ERT, involves the use of enamel
matrix derivatives (EMD, Emdogain1), that contains >90%
amelogenin and <10% other protein.70 A 1-year randomised
controlled trials showed that EMD was superior to the
conventional open flap debridement (OFD).71 Additionally, a
combination therapy of EMD and OFD was significantly
resulted in better clinical outcome than OFD and PrefGel1
in a 5-years randomised controlled study.72 Also, a combina-
tion therapy of GTR and EMD showed better outcome than
single therapies, but this effect was small as shown in
Bayesian network meta-analysis study.73 The use of EMD in
periodontal regeneration was due to its stimulatory effect on
the proliferation and differentiation of human periodontal
ligament cells (HPDLCs).74 From EMD, amelogenin in particu-
lar, was selectively taken by human periodontal ligamentfibroblasts, HPDLFCs, internalised and processed into a 5 kDa
peptide-tyrosine rich amelogenin peptide (TRAP, a specific
amelogenin isoform).75 Synthetically produced TRAP sup-
pressed the osteogenic differentiation of bone precursor cells.
Whereas, another synthetically produced amelogenin iso-
form, a leucine-rich amelogenin peptide (LRAP), enhanced
terminal differentiation of bone-forming cells. This difference
was related to the C-terminal; TRAP has unique C-terminal 12
amino acid sequence (TCT), but LRAP and its unique C-
terminal 23 amino acid sequence (LCT). The differential effect
of TRAP and LRAP can be employed to limit the pathological
bone growth or to enhance bone formation as in the treatment
of periodontal and orthopaedic diseases.76 In addition to its
action on HPDLFCs and bone precursor cells, EMD also acts as a
proangiogenic factor in vitro and accordingly stimulate the
blood vessel formation during periodontal regeneration.77
Tissue regeneration of the periodontium is no longer
considered solely as an experimental approach, and signifi-
cant progress has been made these past 10–15 years with
respect to the development of biodegradable scaffold materi-
als. Today’s concepts of matrix-and scaffold-based tissue
engineering involve the combination of a scaffold with cells
and/or biomolecules that promote the repair and/or regener-
ation of such tissues. More recently, regenerative therapies
have considered whole tissue architecture, the ultimate goal
aimed at the creation of scaffolds that create a temporary 3D
matrix upon which cells and tissues can grow exclusively
in vitro and/or in vivo. The advances made by targeting
particular families of growth factors and other signalling
molecules at both the protein and gene levels has led to
promising results. Much new data have been accumulated
regarding the cell recruitment, attachment and chemotaxis,
proliferation and differentiation, angiogenesis and extracel-
lular matrix production of the regenerated tissue at the site of
disease or damage. However, the results are still relatively
unpredictable and vary greatly among different species and
model systems and, in humans, depend on a host of other
environmental factors which can play an important role in the
successful outcome (or not) of periodontal therapy.
3.3. Bioengineered teeth
Tooth development, odontogenesis, is a complex process
involving a series of reciprocal epithelial–mesenchymal
interactions and coordination between the crown and the
root with its associated periodontium.78 Accordingly, cells
dissociated from epithelium and mesenchymal tissues of
prenatal or postnatal tooth germ were used to reconstitute a
‘‘bioengineered tooth germ’’ in vitro. Transplantation of
bioengineered tooth germ into the oral environment or an
organ culture has been then attempted to produce a whole
tooth.79 Implantation of biodegradable polyglycolic/polylac-
tide scaffolds, having the shape of a tooth and seeded with
cells isolated from dissociated postnatal porcine third molar
tooth buds, into rat hosts for 20–30 weeks successfully
produced recognisable tooth structures (dentine, well defined
pulp chamber, putative Hertwig’s root sheath epithelia,
putative cementoblasts and dental organ with fully formed
enamel). The size of bioengineered tooth however was very
small and did not conform to the shape and size of the
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ated dental ectomesenchyme, the following combinations
were used: (1) dissociated epithelial and mesenchymal cells
(EC-MC), (2) dissociated epithelial cells and intact dental
mesenchyme (EC-MT) and (3) intact dental epithelium with
dissociated mesenchymal cells (ET-MC). As observed, the
intactness of dental mesenchyme is essential for crown
morphogenesis but not for epithelial histogenesis. Absence
of intact dental mesenchyme, however, can be compensated
by increasing the number of dissociated mesenchymal cells
that are available for reassociation with intact dental
epithelium.78 Using prenatal tooth germ cells showed higher
tendency for tooth formation with proper crown shape than
postnatal tooth germ cells.81 Again, the effect of the source and
age of tooth bud on the innate regenerative capacity of the
isolated cells as well as the effect of scaffolds on cell behaviour
required more investigations. As seen, bioengineering of rat
tooth occurred reliably in a shorter time than pig tooth i.e., 12
instead of 25 weeks. Furthermore, the 4-days postnatal (dpn)
rat molar tooth bud cells exhibited the highest cell yield/tooth
bud and viability when compared with 3–7 dpn cells.25 As
expected the natural scaffold e.g., collagen sponge showed
higher degree of success in tooth production than synthetic
scaffold materials e.g., PLGA mesh.82
Regardless of this achievement in tissue engineering of the
whole tooth,79 several challenges must be faced. For example,
optimising the number and quality of dissociated tooth bud
cells requires more investigation. However, due to the limited
availability of autologous tooth bud cells, researching the
possibility of using autogenic somatic stem cells of dental or
non-dental origin (e.g., bone marrow stem cells or oral mucosa
derived epithelial cells) as candidate sources for bioengineer-
ing of whole teeth is also required. Incorporation of growth
factors and cytokines or even transplantation of a regenerated
tooth rather than regenerated tooth bud requires further
consideration. Understanding the events that are involved in
engineering a specific type of teeth (incisors, canines,
premolars or molars) is also crucial. Once getting the required
type of tooth, controlling the anatomy and colour of
bioengineered tooth is another area that requires investiga-
tion.83 Reaching the continuity of the engineered tooth with
the jaw bone by fully functional periodontium and highly
vascularised pulp is also essential for the success of
regeneration. Generally, the time required to regenerate a
whole tooth is also an important factor which requires further
consideration. Thus ‘‘whole-tooth regeneration takes a village
of scientists, clinicians and patients’’.84
3.4. Skin, oral mucosa, facial muscles and salivary glands
Tissue engineering made extensive progress in the area of skin
regeneration and recently several skin substitute products
(epidermal, dermal or composite) are now commercially
available. The pioneering work started by the observation of
entire keratinising colonies from in vitro cultured epidermal
keratinocytes.85 The formation of keratinocytes sheets was
then followed using autogenic or allogenic epidermal cells.86
The keratinocytes sheet has the ability for renewal throughout
the patient’s lifetime87 and can undergo organisation and
differentiation after grafting.88 The keratinocytes sheet,however, is too friable to handle and suture. Grafting
fibroblasts-seeded decellularized dermis, obtained from ca-
daveric skin has been also attempted; the limited availability,
reproducibility and safety of cadaver dermis, however, limited
its use. Engineering bilayered skin or composite graft,
consisting of epidermis and dermis89 then followed. For this
purpose, collagen was the most widely used scaffold since
1956.90 An organotypic engineered skin was firstly employed
to treat wounds in animals91 and then in humans.92 The first
complete model of engineered skin using human cells was
developed in 1991.93 Recently, few composite allografts
produced from decellularised collagen are commercially
available e.g., Apligraf1.94
Due to the similarity between skin and oral mucosa, the
development of engineered oral mucosa followed the same
protocol i.e., started with the development of epithelial sheet,95
then composite oral mucosal equivalent either by seeding oral
keratinocytes on decellularised cadaveric human dermis
(AlloDerm)96 or three-dimensional cell seeded scaffold. Fur-
thermore, both skin and mucosal substitutes can be used
interchangeably.97 Recently, the tissue engineered oral mucosa
has been further improved for either intraoral or extraoral
use.98,99 To reduce the contraction that represented the major
complication of tissue engineered oral mucosa, glutaraldehyde
pretreatment of decellularised dermis and physical restraint of
tissue engineered mucosa during the first phase of culture is
required.98 Due to its resiliency, suppleness and good tolerance,
cross linked collagen membranes also found a great potential as
mucosal grafts following surgical removal of precancerous or
cancerous lesions or application of bone graft in oro-facial
area.100 The commercially available collagen products used for
this purpose include Bio-Col or Mucograft.101 Other polymers
have been also employed to engineer oral mucosa e.g., silk
fibroin that could reduce wound contraction;102 nanofibrous
elastin-like recombinant polymer collagen that was observed to
improve the self-renewal potential of epithelial cells after
grafting103 and collagen-elastin (Matriderm1).104 Moharamza-
deh et al105 have reviewed the synthetic oral mucosa develop-
ments in recent years and quite rightly report that despite being
more physiologically relevant than monolayers; ultimately the
basic structure of the connective tissue component and the
reconstituted basement membrane in such biomimetic models
enables only a simplistic representation of the native stromal
microenvironment. Thus, most researchers in the field of oral
tissue engineering are veering from the more traditional
monolayer cell culture systems to the well-characterised and
reproducible tissue-engineered oral mucosal models that
mimic the native human oral mucosa and are more clinically
relevant, perhaps more informative than the former systems.
Currently, plastic compressed collagen has been extensively
investigated as a potential scaffold for skin or mucosal grafting
procedures.106
Facial muscles have unique anatomy and fibre composition
compared to other skeletal muscles. Tissue engineering
therefore holds promise for future treatment of patients with
facial paralysis107 and partial tongue resection.108 Finding a 3-
D scaffold that fulfils the demands of biocompatibility,
elasticity and stability is a key issue for the clinical application
of tissue engineered muscle.109 Moreover, using the appropri-
ate muscle progenitor cell that shows high proneness to
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acteristics and contractility as the donor muscle, e.g., satellite
cells, is another essential issue for engineering the facial
muscles. In vivo, satellite cells respond to hypoxic, ischaemic
muscle damage by differentiation into myotubes (immature
muscle fibre) and maturation to muscle fibres.110 In vitro,
however, the efficiency of satellite cell differentiation is
suboptimal; microRNA-1 and 206 however improved the
human satellite cell differentiation by increasing the myogen-
ic regulators.111 Other cell population e.g., fibroblasts are also
required to assist in the self-assembly of tissue engineered
muscle.112 Vascularisation and innervations of the muscle
construct remains a major challenge in tissue engineering.113
Applying an optimal electrical, chemotropic and mechanical
stimulus is therefore essential for functional reconstruction of
facial muscles.114 Various tissue engineering strategies have
been currently researched for regeneration of facial muscles.
For example, in vivo implantation of a preformed tissue
engineered muscle, made from neonatal rat myoblast seeded
collagen constructs, into the face of rats was successful in
regeneration of active myofibers, nerve fibres and blood
vessels.107 Implantation of myoblasts seeded collagen con-
structs was also effective in promoting volume preservation
and/or tongue reconstruction.108 Injection of platelet-rich
plasma, growth factors and stem cell-based strategy has been
also employed. The use of these biological therapies however
requires a standardised, safe use in the clinic and careful
understanding of the mechanisms involved in the survival,
proliferation and differentiation of stem cells and in muscle
regeneration as a whole.115
Treatment of salivary glands’ hypofunction following
irradiation in head and neck area is only limited to the
administration of saliva substitutes and sialogogues that
require frequent administration. Tissue engineering provides
a biological substitute to impaired salivary glands. The main
challenge however is to culture the human salivary gland cells
as they are highly differentiated and difficult to expand
in vitro. Using low-calcium system was found to be effective in
enabling the human parotid gland acinar cells (PGAC) to
continuously proliferate, maintain their phenotype and
express both secretory (a- amylase) and function-related
proteins (e.g., (aquaporin-3, aquaporin-5, and ZO-1)). Further-
more, these cells were able to form 3D cell aggregates, called
post-confluence structures (PCSs), which were able to produce
high level of function-related proteins than 2D cells. The use of
2D scaffold is however still possible to engineer salivary
glands.116 Primary human salivary gland cells seeded biode-
gradable polymer scaffolds showed the formation of post-
confluence structure in vitro by enhancing E-cadherin
expression117 and acinar gland-like structure after 4 weeks
of subcutaneous implantation in athymic mice. The gland-like
structure also showed the production of human salivary a-
amylase (acinar cell protein).118 Selective functionalisation of
degradable scaffold with chitosan and/or laminin-111 provide
chemical signals that support proliferation of epithelial cells
and promoted the apicobasal polarity, required for directional
secretion by secretary cells.119 Gene therapy is another
potential approach for salivary gland regeneration. It relies
on the using of a recombinant adenovirus to deliver a water-
channel protein gene (aquaporin) to the surviving ductalepithelial cells. This gene is capable of transforming the ductal
cells into acinar-like cells (i.e., saliva secreting cells) when
integrated into their basement membranes.120 Phase I clinical
trial on the use of adenovirus containing human aquaporin is
currently underway to treat patients with salivary glands
hypofunction.121
Over the last three decades, there was a great progress in
treating various burns and skin/mucosa-related disorders.
This progress has been considered as a breakthrough due to
the uniqueness and complexity of the tissue engineered. The
presence of several products available for clinical use is
testimony of the success of tissue engineering in this area of
the body. The greatest challenge however is the complexity to
mimic the host tissues. Therefore engineering a fully
functional skin is one of the greatest challenges in tissue
engineering due to the various compositions and functions of
different layers of the skin. Furthermore, the development of
an effective interface between epidermis and dermis in a full
engineered skin is also challenging. Developing a product that
can be used interchangeably for both skin and oral mucosa is
also highly challenging as it is expected from the same product
to behave differently under different situations i.e., has hair
when used for skin regeneration but not for mucosa. Other
limiting factors would be convenience of use, clinical efficacy
and patient safety of the end-product. Engineering a fully
functional skin replacement will therefore require the
development of new scientific strategies and further thorough
investigations to meet the patients’ need with best effective
and cheap replacement. Using the recent technology of ‘‘ultra-
rapid plastic compression’’ could offer a great prospect for the
development of asymmetric meso-scaled lamellar (multilay-
ered) structures of compacted, aligned collagen fibrils that
vary in density across the layers. These hierarchical structures
could mimic the stratification, mechanical properties and
complexity of the natural tissues.
3.5. Bone and temporomandibular joints
Application of autogenic periosteal cells-seeded polymer
fleeces to augment the floor of the maxillary sinus before
implants insertion showed encouraging results from both
radiographical and histological examinations.122 For irregular
defects, injectable composites [e.g., b-TCP/alginate123 and
CPC-chitosan124] could be useful for stem cell-based bone
engineering. Autogenic growth factors-rich plasma in combi-
nation with inorganic bone (Bio-Oss1) has been also employed
clinically in sinus floor elevation; this treatment was effective
in forming new vascularised bone.125
Temporomandibular joint (TMJ) is one of the most difficult
tissues to treat due to the limited blood supply and hence
limited capacity for self-repair. Patients suffering from TMJ
disorders often experience pain during normal activities e.g.,
eating and speaking accordingly they have low quality of life
(Fig. 3) showed diseased vs. normal TMJ. The articular cartilage
of TMJ has a surface layer of fibrocartilaginous and deep layer
of hyaline-like hypertrophic zone with a thin intermediate
proliferative zone. For regeneration of this unique cartilage,
cell therapy comes first and injectable smart hydrogels could
be employed to transfer cells.126 As known, the autogenic cells
are the gold standard cell source used for tissue regeneration,
Fig. 3 – Panoramic X-ray showing normal TMJ, indicated by red circles (a) versus diseased TMJ (b). Close view of TMJ (c). (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)
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TMJ. Accordingly, finding another cell source would be an
essential in such case e.g., human umbilical cord derived
mesenchymal-like stem cells (HUCM)127 or primary costal
chondrocytes (CCs)128 or hyaline cartilage cells from anywhere
in the body129 may be an alternative to TMJ condylar cartilage.
Since bone and cartilage require different competing
conditions for their regeneration, growing a biphasic osteo-
chondral construct in vitro is therefore very challenging. Ultra
rapid tissue engineering techniques coupled with gradient-
based scaffolding and a single cell population provide a
potentially promising approach for future biological joint
replacement. In such condition, hyper-hydrated collagen gels,
for example, seeded with hMSCs preconditioned in an
osteogenic media at one end but preconditioned in a
chondrogenic media at the other end. The development of
distinct bone-like and cartilage-like areas and mimicking a
primordial joint-like structure has been demonstrated after 7
days of an in vitro culture.130 The same concept of fabricating
gradient-based scaffolding was also applied to poly(D,L-lactic-
co-glycolic acid) microspheres. The gradation in such case was
obtained by having growth factors instead of cells with
different potentials e.g., cartilage-promoting TGF-1 at the
cartilaginous end but bone-promoting BMP-2 growth factors at
the bony end of the construct. In such case, a newly formed
osteochondral tissue was observed in a small mandibular
condyle osteochondral defect in New Zealand rabbits after 6
weeks of implantation.131
Regarding the TMJ disc, acellular porcine-derived ECM was
effective as inductive template for reconstruction of TMJ disc
when implanted in vivo for 6 months and it has been assumed
that this bioscaffold represents an off-the-shelf solution for
engineering of TMJ disc.132 Regarding the cellular component,
adipose stem cells (ADSCs) could be a potential cell source for
TMJ engineering.133 Furthermore, platelet-derived growth
factor (PDGF) could be an effective for engineering of TMJ
disc. PDGF within an optimal concentration of 5 ng/ml
significantly increased the proliferation rat of the TMJ-disc
derived cells, collagen and hyaluronic acid synthesis. It also
upregulated RNA levels of type I and II collagens, matrix
metalloproteinases (MMPs), and tissue inhibitors of metallo-
proteinases (TIMPs).134 Basic fibroblast growth factor (bFGF),135
transforming growth factor-b1 (TGF-b1) and insulin-like
growth factor-1 (IGF-1)136 have been also investigated for
potential application in TMJ disc regeneration. All these
growth factors have been shown to induce bone marrow
mesenchymal stem cell differentiation into fibroblast-likecells, which could synthesise TMJ disc matrix of GAG and type I
collagen.
The approaches employed to overcome the challenge of
TMJ engineering have been varied from cell injection therapy
to the use of synthetic or natural scaffolds as well as relying to
some extent on biological modulators; each with varying
degree of success. The critical outcome of the success of all
engineered TMJ replacements, however, will not only be
measured by the restoration of function; the prevention of
fibrous or ossified adhesions, the main complications of many
surgical interventions, is also considered as a key factor in the
success in clinical applications. Therefore, in designing TMJ
replacement, incorporation of signalling molecules that allow
for rapid and convenient tissue replacement but also prevent
adhesions or ossification of the replaced tissue would be very
challenging. Furthermore, engineering the osteochondral
interface with its complex structure and its cartilaginous
component with its zones of different structures and
organisation is very challenging. To engineer such spatial
complexity, designing scaffolds recapitulating the gradients in
the regulatory signals between different cell types through
understanding of the molecular cross talk between cells at the
interface is required.
4. Concluding remarks and outlook
Tissue engineering provides a new era for therapeutic medicine;
it is progressing very rapidly and extends to involve all tissues in
our body. Three decades ago, tissue engineering was an idea and
today it has become a potential therapy for several conditions.
For a more regenerative breakthrough to develop and lead to
off-the-shelf bioproducts to replace a variety of lost tissues and
organs, a thorough understanding of embryonic development
and stem cell biology are required. Regenerating oral tissues, in
particular, is very challenging and requires recapitulation of the
biological development of several tissues and interfaces.137 The
progress in this field is taking several routes including; cell
biology, the development of novel scaffolds/fabrication meth-
ods/characterisation techniques. Stem cell therapy and engi-
neering of irreversibly damaged tissues becomes less fictional
and is actually progressing towards a reality. Since most of the
current or emerging paradigms in tissue engineering have
limited and variable outcomes; a true and biological tissue
regeneration in not yet achievable. Translating tissue engineer-
ing research and development into clinical practice still drives
much of science and technology in this field.61
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significant changes in the more traditional areas of clinical
dentistry are beginning to occur. Thus, there has been a recent
surge in guided tissue engineering methods to establish new
therapies to manage periodontal diseases beyond the tradi-
tional approaches based solely upon infection control.138
Periodontal diseases are some of the most common oral
diseases worldwide, after caries, and have been found to have
a role in more general systemic diseases such as diabetes and
cardiovascular disease. The need for more reproducible oral
tissue replacement therapies is therefore considerable. To
date, the regeneration of small or medium-sized periodontal
defects using in vitro engineered cell-scaffold constructs is
technically feasible, and some of the current products
available on the market offer alternatives for selected clinical
scenarios. These include Emdogain, Orthoss and BioOss.
However, the predictable reconstruction of the innate organi-
sation and function of whole teeth as well as their periodontal
structures remains challenging. Future possibilities depend on
an improved fundamental understanding of cellular and
molecular mechanisms involved in the regeneration of all
periodontal tissues, the differentiation potential of stem cells,
and the biocompatibility stem cells and materials with host
tissues. Major bone reconstructions because of trauma,
cancer, or augmentation for dental implants are current
examples of how tissue engineering can be also be used for
craniofacial applications.139
The addition of various protein factors onto implant/
material surfaces is also a current approach being widely
investigated. While the addition of these growth factors is an
exciting perspective, many questions still remain unanswered
with respect to application mechanisms of these proteins and
the control of their release pattern, increasing the time that
they are bioactive and maximising their biological regenera-
tive potential. However, this approach has some conse-
quences such as the high cost of preparation, and protein
concentration is crucial to reduce any toxicity/side effects;
considerations that must be factored for this approach to
become affordable and clinically safe.
The most recent advances in restorative dentistry involve
the development, techniques and materials to regenerate the
whole tooth complex in a biological manner. Tissue engineer-
ing-based approaches certainly have the potential to achieve
this and the future research drive seems to be diverting from a
metal-based implant to a biological, cell-based one. Thus, the
absolute minimum requirement for tooth regeneration of this
type is the successful formation of a heterogenous and
dynamic array of tissues including roots, the periodontal
ligament, nerve and vascular tissues, as well as the essential
dentine-pulp complex. Perhaps the least important anatomi-
cal structures are the mineralised tissues of the crown as
current synthetic tooth crowns function more than adequate-
ly, as well as being matched for size, shape, colour and
occlusion.140
Despite some limited progress and minor successes, there
remain distinct and important challenges in the development
of reproducible and clinically safe approaches for oral tissue
repair and regeneration. Clearly, there is a convincing body of
evidence which confirms the need for this type of treatment,
and public health data worldwide indicates a more thanadequate patient resource. The future of these therapies
involving more biological approaches and the use of dental
tissue stem cells is promising and advancing. As more and
more information is collated and knowledge acquired with
respect to dental stem cells and tissues, there may well be a
significant interest of their application and wider potential to
treat disorders beyond the craniofacial region of the body.
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